Deficiency, it can be used as an antihypertensive rather than for the control of hirsutism. Due to the low incidence of adrenal crisis and other severe symptoms in untreated 17-OHD, the diagnosis is often delayed. Patients usually present around adolescence or at the pubertal age and the awareness of the clinician about this condition is very important so that diagnosis should not be missed.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Anvesh Golla, Sreebhushan Raju, Krishna Prasad

Department of Nephrology, Nizams Institute of Medical Sciences, Hyderabad, Telangana, India

Address for correspondence:
Dr. Sreebhushan Raju,
Department of Nephrology, Nizams Institute of Medical Sciences, Punjagutta, Hyderabad - 500 082, Telangana, India.
E-mail: Sreebhushan@hotmail.com

Hyperkalemia Unveiled: A Case of Barakat Syndrome

Here we present an interesting case of Barakat syndrome with resistant hyperkalemia due to hyporeninemic hypoaldosteronism (Type 4 renal tubular acidosis). Barakat or HDR syndrome is an autosomal dominant disorder that consists of triad of hypoparathyroidism, sensorineural deafness, and renal dysplasia. As per our knowledge, we report the first case of Barakat syndrome presenting with resistant hyperkalemia and convulsions.

A 39-year-old female was admitted with history of recurrent episodes of generalized seizures due to hypocalcemia despite being on oral calcium and sodium valproate and easy fatiguability for 3 months. Neuroimaging was normal. Further history revealed progressive hearing loss for last 6 years with bilateral moderate sensorineural hearing loss on audiometry. Laboratory parameters revealed blood urea of 60 mg/dl, serum creatinine 1.7 mg/dl, serum potassium 6.6 mEq/L, chloride 115 mEq/L serum calcium 3.9 mg/dl, albumin 4.6 g/dl, serum bicarbonate 18 mEq/L, serum anion gap 12 mEq/L (normal 8-16 mEq/L) and phosphorus 10.5 mg/dL. Electrocardiography demonstrated prolonged QT interval (0.52 sec) and tall T waves. Ultrasound abdomen showed a solitary right kidney with raised echogenicity. Further investigations yielded very low PTH of 0.23 pg/ml (normal range 15-65 pg/ml) by electrochemiluminescence immunoassay (ECLIA) and high TSH 22 miU/l (normal range 0.4-4 miU/l). Her urine examination revealed 770 mg of proteinuria in 24 hours urine collection. There was no history of diabetes, hypertension, fever, neck surgery or irradiation. There was no significant family history.
Initially, she was managed with anti-hyperkalemic treatment in the form of dextrose insulin drip, furosemide, oral bicarbonate supplements, polystyrene exchange resins and low potassium diet but continued to have hyperkalemia (potassium 6.1 mEq/L). A possibility of hyporeninemic hypoaldosteronism was considered based on normal anion gap hyperchloremic metabolic acidosis and low transtubular potassium gradient of 2 (normal >4). However, her serum aldosterone level was normal. She was started on fludrocortisone 100 µg daily and within 2 days her potassium decreased to 4 mEq/L. Renal involvement, hypoparathyroidism and sensorineural deafness completed our clinical triad of Barakat syndrome. Genetic mutation analysis could not be done due to financial constraints. The patient was continued on maintenance dose of fludrocortisone (50 µg/day), calcium carbonate, thyroxine, ergocalciferol, calcitriol and sodium valproate. She is maintaining normal levels of potassium and calcium with no further seizure episode.

Barakat syndrome (HDR syndrome) is caused by haploinsufficiency of the GATA3 gene on chromosome 10p15 and patients with this syndrome usually have initial symptoms related to hypocalcemia. It was first reported in 1977 by Barakat et al. GATA3 belongs to GATA transcription factor families, which are involved in vertebrate embryonic development of the parathyroid glands, inner ears, kidney, thymus, and central nervous system. Hypoparathyroidism causes symptomatic or asymptomatic hypocalcemia by normal or inappropriately low levels of parathyroid hormone (PTH) secretion. Sensorineural deafness is a consistent feature, which is more severe at higher frequencies and usually bilateral. Severity of renal involvement also varies from no renal abnormalities to renal dysplasia, hypoplasia, cystic kidneys, vesicoureteral reflux and most patients progress to advanced chronic kidney disease requiring renal replacement therapy. Diagnosis is generally based on clinical findings, though DNA analysis will aid in definitive diagnosis by showing haploinsufficiency or submicroscopic deletion on chromosome 10p. Treatment of this syndrome is symptomatic, treating the clinical abnormalities associated with HDR syndrome. Prognosis of HDR syndrome is varied depending on the nature and severity of the renal disease.

This is an unusual presentation with hyperkalemia. This has not been reported in any previous case reports, though renal tubular acidosis (type 1 and 2) have been reported earlier too. There are case reports involving multiple endocrine organ involvement. This patient too was having associated thyroid involvement. Hyperkalemia was responding to empirical fludrocortisone so probably it was due to type 4 Renal Tubular acidosis (hyporeninemic hypoaldosteronism) along with early renal dysfunction.

To conclude, Barakat or HDR syndrome should be suspected in a patient with deafness, hypocalcemia and renal dysfunction and one should always think of hyporeninemic hypoaldosteronism in situation of unexplained hyperkalemia with mild renal dysfunction.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent forms. In the form the patient(s) has/have given his/her/ their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

Kulwant Singh, Jasmine Sethi, Vinant Bhargava

Consultant Division of Nephrology, Grecian Hospital, Sector 69, Mohali, Punjab, Department of Nephrology, Institute of Renal Sciences, Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi, India

Address for correspondence:
Dr. Kulwant Singh,
Consultant Division of Nephrology, Grecian Hospital, Sector 69, Mohali, Punjab, India.
E-mail: kulmin2k@gmail.com

References

1. Barakat AY, D’Albora JB, Martin MM, Jose PA. Familial nephrosis, nerve deafness, and hypoparathyroidism. J Pediatr 1977;91:61-4.
2. Bilous RW, Murty G, Parkinson DB, Thakker RV, Coulthard MG, Burn J, et al. Brief report: Autosomal dominant familial hypoparathyroidism, sensorineural deafness, and renal dysplasia. N Engl J Med 1992;327:1069-74.
3. Van Esch H, Groenen P, Nesbit MA, Schuffenhauer S, Lichtner P, Vanderlinden G, et al. GATA3 haplo-insufficiency causes human HDR syndrome. Nature 2000;406:419-22.
4. Maleki N, Bashardoust B, Iranparvar Alamdari M, Tavosi Z. Seizure, deafness, and renal failure: A case of barakat syndrome. Case Rep Nephrol 2013;2013:261907.
5. Taslimipar A, Kebapcilar L, Kutlu M, Sahin M, Aydogdu A, Uckayla G, et al. HDR syndrome (hypoparathyroidism, sensorineural deafness and renal disease) accompanied by renal tubular acidosis and endocrine abnormalities. Intern Med 2008;47:1003-7.

Access this article online

Quick Response Code: Website: www.indianjnephrol.org DOI: 10.4103/ijn.IJN_132_19

How to cite this article: Singh K, Sethi J, Bhargava V. Hyperkalemia unveiled: A case of Barakat syndrome. Indian J Nephrol 2020;30:135-6.

Received: 18-04-2019; Revised: 01-06-2019; Accepted: 09-06-2019; Published: 03-01-2020.

© 2019 Indian Journal of Nephrology | Published by Wolters Kluwer - Medknow